Characterization of the anxiolytic and sedative profile of JM-20: a novel benzodiazepine–dihydropyridine hybrid molecule

References

• Yang Y, Shuaib A, Li Q, Siddiqui MM. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res. 1998;804:169–76.
   PubMed Web of Science ®Google Scholar
• Schwartz-Bloom RD, Sah R. gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. J Neurochem. 2001;77:353–71.
   PubMed Web of Science ®Google Scholar
• Leist M, Nicotera P. Apoptosis, excitotoxicity, and neuropathology. Exp Cell Res. 1998;239:183–201.
   PubMed Web of Science ®Google Scholar
• Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS – what is the evidence? J Neurol. 2000;247:I7–16.
   Web of Science ®Google Scholar
• Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, et al.. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008;51:347–72.
   PubMed Web of Science ®Google Scholar
• Minnerup J, Schäbitz WR. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics. 2009;6:43–52.
   PubMed Web of Science ®Google Scholar
• Corbett D, Larsen J, Langdon KD. Diazepam delays the death of hippocampal CA1 neurons following global ischemia. Exp Neurol. 2008;214:309–14.
   PubMed Web of Science ®Google Scholar
• Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483–94.
   PubMed Web of Science ®Google Scholar
• Iwata M, Inoue S, Kawaguchi M, Furuya H. Effects of diazepam and flumazenil on forebrain ischaemia in a rat model of benzodiazepine tolerance. Br J Anaesth. 2012;109:935–42.
   PubMed Web of Science ®Google Scholar
• Sarnowska A, Beręsewicz M, Zabłocka B, Domańska-Janik K. Diazepam neuroprotection in excitotoxic and oxidative stress involves a mitochondrial mechanism additional to the GABAAR and hypothermic effects. Neurochem Int. 2009;55:164–73.
   PubMed Web of Science ®Google Scholar
• Babu CS, Ramanathan M. Post-ischemic administration of nimodipine following focal cerebral ischemic-reperfusion injury in rats alleviated excitotoxicity, neurobehavioural alterations and partially the bioenergetics. Int J Dev Neurosci. 2011;29:93–105.
   PubMed Web of Science ®Google Scholar
• Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HWS, Frick R, et al.. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev. 2000;23:145–50.
   PubMed Web of Science ®Google Scholar
• Zapater P, Moreno J, Horga JF. Neuroprotection by the novel calcium antagonist pca50938, nimodipine and flunarizine, in gerbil global brain ischemia. Brain Res. 1997;772:57–62.
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol. 2011;4:293–98.
   PubMedGoogle Scholar
• Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248–54.
   PubMed Web of Science ®Google Scholar
• Schwartz-Bloom RD, Miller KA, Evenson DA, Crain BJ, Nadler JV. Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: an ultrastructural study. Neuroscience. 2000;98:471–84.
   PubMed Web of Science ®Google Scholar
• Alba Guitiérrez LL, Carillo Domínguez C, Nuñez Figueredo Y, Ochoa Rodriguez E, Pardo Andreu GL, Ruiz Reyes A, et al.. Tricyclic and tetracyclic system with activity on the central nervous and vascular systems. Publication No. EP2487174 A2 CU Patent 2009-0172. Available at: http://www.google.com/patents/EP2487174A2?cl = en (accessed 11 April 2013).
   Google Scholar
• Archer J. Tests for emotionality in rats and mice: a review. Anim Behav. 1973;21:205–35.
   PubMed Web of Science ®Google Scholar
• Walsh RN, Cummins RA. The open-field test: a critical review. Psychol Bull. 1976;83:482–504.
   PubMed Web of Science ®Google Scholar
• Pinna G, Dong E, Matsumoto K, Costa E, Guidotti A. In socially isolated mice, the reversal of brain allopregnanolone down-regulation mediates the anti-aggressive action of fluoxetine. Proc Natl Acad Sci USA. 2003;100:2035–40.
   PubMed Web of Science ®Google Scholar
• Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1988;2:145–81.
   PubMed Web of Science ®Google Scholar
• Chauhan K, Sheth N, Ranpariya V, Parmar S. Anticonvulsant activity of solasodine isolated from Solanum sisymbriifolium fruits in rodents. Pharm Biol. 2011;49:194–9.
   PubMed Web of Science ®Google Scholar
• Dawson GR, Tricklebank MD. Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends Pharmacol Sci. 1995;16:33–6.
   PubMed Web of Science ®Google Scholar
• Moreira ELG, Rial D, Duarte FS, De Carvalho CR, Horst H, Pizzolatti MG, et al.. Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats. J Pharm Pharmacol. 2010;62:1061–8.
   PubMed Web of Science ®Google Scholar
• Ellinwood EH, Balster RL. Rating the behavioral effects of amphetamine. Eur J Pharmacol. 1974;28:35–41.
   PubMed Web of Science ®Google Scholar
• OECD. Guideline for testing of chemicals. 423 Acute Oral Toxicity – Acute Toxic Class Method. 2001.
   Google Scholar
• Rex A, Voigt JP, Voits M, Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav. 1998;59:677–83.
   PubMed Web of Science ®Google Scholar
• Eloqayli H, Qu H, Unsgård G, Sletvold O, Hadidi H, Sonnewald U. Effects of pentylenetetrazole and glutamate on metabolism of [U-(13)C]glucose in cultured cerebellar granule neurons. Neurochem Int. 2002;40:181–7.
   PubMed Web of Science ®Google Scholar
• Pittson S, Himmel A, MacIver M. Multiple synaptic and membrane sites of anesthetic action in the ca1 region of rat hippocampal slices. BMC Neurosci. 2004;5:1–10.
   PubMed Web of Science ®Google Scholar
• Tanelian DL, Kosek P, Mody I, Maclver MB. The role of the GABAA receptor/chloride channel complex in anesthesia. Anesthesiology. 1993;78:757–76.
   PubMed Web of Science ®Google Scholar
• Lin HQ, Burden PM, Johnston GAR. Neuropharmacology: Propylene glycol elicits anxiolytic-like responses to the elevated plus-maze in male mice. J Pharm Pharmacol. 1998;50:1127–31.
   PubMed Web of Science ®Google Scholar
• Robl JA, Cimarusti MP, Simpkins LM, Brown B, Ryono DE, Bird JE, et al.. Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. J Med Chem. 1996;39:494–502.
   PubMed Web of Science ®Google Scholar
• Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci. 2012;2012:19.
   Google Scholar
• Wilson SC, Howard PW, Forrow SM, Hartley JA, Adams LJ, Jenkins TC, et al.. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2,1-c][1,4]benzodiazepine system. J Med Chem. 1999;42:4028–41.
   PubMed Web of Science ®Google Scholar
• Wyatt PG, Allen MJ, Chilcott J, Hickin G, Miller ND, Woollard PM. Structure–activity relationship investigations of a potent and selective benzodiazepine oxytocin antagonist. Bioorg Med Chem Lett. 2001;11:1301–5.
   PubMed Web of Science ®Google Scholar
• Sherrill RG, Berman JM, Birkemo L, Croom DK, Dezube M, Ervin GN, et al.. 1,4-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonists. Bioorg Med Chem Lett. 2001;11:1145–8.
   PubMed Web of Science ®Google Scholar
• Prut L, Belzung C. The open-field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463:3–33.
   PubMed Web of Science ®Google Scholar
• Crawley JN. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav. 1981;15:695–9.
   PubMed Web of Science ®Google Scholar
• Rex A, Stephens DN, Fink H. ‘Anxiolytic’ action of diazepam and abecarnil in a modified open-field test. Pharmacol Biochem Behav. 1996;53:1005–11.
   PubMed Web of Science ®Google Scholar
• Gourley SL, DeBold JF, Yin W, Cook J, Miczek KA. Benzodiazepines and heightened aggressive behavior in rats: reduction by GABA(A)/alpha(1) receptor antagonists. Psychopharmacology. 2005;178:232–40.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Puia G, Dong E, Pinna G. GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders. Stress. 2007;10:3–12.
   PubMed Web of Science ®Google Scholar
• Bond AJ. Drug-induced behavioural disinhibition: incidence, mechanisms and therapeutic implications. CNS Drugs. 1998;9:41–57.
   Web of Science ®Google Scholar
• Ferrari PF, Parmigiani S, Rodgers RJ, Palanza P. Differential effects of chlordiazepoxide on aggressive behavior in male mice: the influence of social factors. Psychopharmacology. 1997;134:258–65.
   PubMed Web of Science ®Google Scholar
• Liao Y-J, Zhai H-F, Zhang B, Duan T-X, Huang J-M. Anxiolytic and sedative effects of dehydroeffusol from Juncus effusus in mice. Planta Med. 2011;77:416–20.
   PubMed Web of Science ®Google Scholar
• Leeb-Lundberg F, Snowman A, Olsen RW. Barbiturate receptor sites are coupled to benzodiazepine receptors. Proc Natl Acad Sci USA. 1980;77:7468–72.
   PubMed Web of Science ®Google Scholar
• Asano T, Ogasawara N. Stimulation of GABA receptor binding by barbiturates. Eur J Pharmacol. 1982;77:355–7.
   PubMed Web of Science ®Google Scholar
• Schröder H, Becker A, Lössner B. Glutamate binding to brain membranes is increased in pentylenetetrazole-kindled rats. J Neurochem. 1993;60:1007–11.
   PubMed Web of Science ®Google Scholar
• Walsh LA, Li M, Zhao T-J, Chiu TH, Rosenberg HC. Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with no effect on benzodiazepine binding site density. J Pharmacol Exp Ther. 1999;289:1626–33.
   PubMed Web of Science ®Google Scholar
• Getova D, Froestl W, Bowery NG. Effects of GABAB receptor antagonism on the development of pentylenetetrazol-induced kindling in mice. Brain Res. 1998;809:182–8.
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990;42:223–86.
   PubMed Web of Science ®Google Scholar
• Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36:S2–12.
   PubMed Web of Science ®Google Scholar
• Rodger C, Pleuvry BJ. Protective effect of flunarizine and nifedipine alone and in combination with anticonvulsant drugs against PTZ-induced seizures in mice. Neuropharmacology. 1993;32:257–63.
   PubMed Web of Science ®Google Scholar
• Navidpour L, Shafaroodi H, Miri R, Dehpour AR, Shafiee A. Lipophilic 4-imidazoly-1,4-dihydropyridines: Synthesis, calcium channel antagonist activity and protection against pentylenetetrazole-induced seizure. Il Farmaco. 2004;59:261–9.
   PubMedGoogle Scholar
• Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 1986;24:525–9.
   PubMed Web of Science ®Google Scholar
• Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev. 1986;11:157–98.
   Web of Science ®Google Scholar
• Mehta VL, Malhotra CL. Anticonvulsant and some neuropharmacological properties of 2-methyl-3-o-tolyl-6-chloro-4(3H)-quinazolone and related compounds. J Pharm Pharmacol. 1966;18:536–9.
   PubMed Web of Science ®Google Scholar
• Sun T, Hu G, Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol. 2009;602:334–42.
   PubMed Web of Science ®Google Scholar
• Dunne F, O′Halloran A, Kelly JP. Development of a home cage locomotor tracking system capable of detecting the stimulant and sedative properties of drugs in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1456–63.
   PubMed Web of Science ®Google Scholar
• Chen JWY, Naylor DE, Wasterlain CG. Advances in the pathophysiology of status epilepticus. Acta Neurol Scand. 2007;115:7–15.
   PubMed Web of Science ®Google Scholar
• Letizia Trincavelli M, Da Pozzo E, Daniele S, Martini C. The GABAA-BZR complex as target for the development of anxiolytic drugs. Curr Top Med Chem. 2012;12:254–69.
   PubMed Web of Science ®Google Scholar
• Yin D-M, Chen Y-J, Sathyamurthy A, Xiong W-C, Mei L. Synaptic dysfunction in schizophrenia. In: , Kreutz MR, Sala C (eds). Synaptic plasticity. Vienna: Springer; 2012. p. 493–516.
   Google Scholar